Addressing Unmet Clinical Needs with Radiopharmaceutical Technologies
Blue Earth Diagnostics is committed to transforming the clinical management of patients with cancer in areas of unmet clinical need. We are focused on developing advanced imaging technologies and therapeutic radiopharmaceuticals, which have potential utility in both diagnostic imaging and cancer treatment. These technologies can help physicians detect cancer, make decisions about patient care and, potentially, help to treat cancer.
We conduct scientific studies, called clinical trials, to find better ways to identify the location of cancer in the body and understand if it can be effectively treated. Some of our clinical trials provide information on the benefits, side effects and possible uses for new technologies. Other trials explore new uses for existing imaging technologies. Results from clinical trials are submitted for review to Regulatory Authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory agencies have strict standards for the review of the safety and effectiveness of new technologies/medicines or new uses of existing technologies/medicines. If these standards are achieved, a technology/medicine may be approved and become available by prescription.
Patients or their physicians who are interested in Blue Earth Diagnostics’ clinical trials can find further details, including clinical trial locations and contact information, by clicking on these links (you will leave this website and go to an external one – Blue Earth Diagnostics is not responsible for the availability and content of the external website):
- Study to Establish Image Interpretation Criteria for 18F-Fluciclovine PET* in Detecting Recurrent Brain Metastases (PURSUE): NCT04410367
- Study to Establish the Diagnostic Performance of 18F-Fluciclovine PET* in Detecting Recurrent Brain Metastases (REVELATE): NCT04410133
*PET = positron emission tomography